On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Save 20% on PRs and Gain Exclusive Benefits with NNW Prime! Click to View Details
WednesdayApr 05, 2017 12:33 pm

NetworkNewsBreaks – Matinas BioPharma Holdings, Inc. (NYSE: MTNB) Receives ‘Buy’ Rating, $8 PT at Aegis Capital

Aegis Capital has issued a ‘Buy’ rating and price target of $8 on shares of Matinas BioPharma’s (NYSE: MTNB) stock. The news follows the company’s report of financial results for the year ended December 31, 2016, for which the company reported cash and cash equivalents of approximately $4.1 million. The analyst noted this cash position and said he expects the company to end the first quarter of 2017 with approximately $14 million and enough cash to fund operations through the second quarter of 2018. The company also recently provided a clinical update, such as plans to initiate a study of…

Continue Reading

WednesdayApr 05, 2017 12:16 pm

NetworkNewsBreaks – Plug Power, Inc. (NASDAQ: PLUG) Inks Deal with Amazon (NASDAQ: AMZN); Shares Surge

Shares of Plug Power (NASDAQ:PLUG) jumped more than 60% early morning after the energy solutions provider announced its agreement with Amazon (NASDAQ: AMZN) in which the e-commerce company will utilize Plug Power fuel cells and hydrogen technology at select fulfillment center locations.  Amazon will begin powering its industrial equipment using the GenKey technology to achieve faster charging times and reduced costs while supporting energy-efficiency in fulfillment operations. Revenues associated with the commercial agreements are expected to be around $70 million in 2017. “This agreement is a tremendous opportunity for Plug Power to further innovate and grow while helping to support…

Continue Reading

WednesdayApr 05, 2017 11:14 am

NetworkNewsBreaks – ChineseInvestors.com, Inc. (CIIX) Attending ‘Invest 2017’ Exhibition

Market analysis company ChineseInvestors.com, Inc. (OTCQB: CIIX) this morning announced plans to attend the ‘Invest 2017’ exhibition, which is set to take place on April 7-8 in Stuttgart, Germany. Noted as the leading trade fair and congress for finance and investment in Germany, Invest 2017 is expected to provide CIIX with an opportunity to introduce its media and nutritional hemp companies to a crowd of German investors. “I am delighted that CIIX is invited to attend Invest 2017 as an exhibitor,” Warren Wang, founder and CEO of CIIX, stated in this morning’s news release. “This exhibition provides CIIX a valuable…

Continue Reading

WednesdayApr 05, 2017 10:38 am

NetworkNewsBreaks – Net Element, Inc. (NASDAQ: NETE) Subsidiary Adds Apple Pay Support in Russia

Mobile payment technology company Net Element, Inc. (NASDAQ: NETE), through its PayOnline subsidiary, this morning announced the launch of Apple Pay support for its Russian markets. “As the shift to mobile payments continues, PayOnline delivers the necessary support and tools merchants need to make payments a seamless part of online and mobile purchases,” Marat Abasaliev, head of online solutions for PayOnline, stated in the news release. “By delivering support to merchants that use Apple Pay, PayOnline demonstrates its ability to meet the growing demand for secure, convenient and quick transactions.” According to data from Apple, the global number of Apple…

Continue Reading

WednesdayApr 05, 2017 10:11 am

NetworkNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) Announces Sale of Brilliant Hallmark Stake

India Globalization Capital, Inc. (NYSE MKT: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning announced the sale of its investment interest in Brilliant Hallmark for a consideration of four million shares of IGC. The shares, which were previously issued to Brilliant Hallmark on August 4, 2016, will be returned and retired, while the Brilliant Hallmark investment will be removed from the company's balance sheet with an associated reduction of roughly $1.88 million. Per this morning’s update, IGC does not expect to record a gain or loss from this transaction. “This strategic move is…

Continue Reading

TuesdayApr 04, 2017 3:52 pm

NetworkNewsBreaks – Top 10 Mid-day Percentage Gainers on April 4, 2017

Here is a list of stocks shaking up the markets today, with particular focus on NASDAQ and OTC small caps. The top gainers based on percentage: BNTC 61.49% – News: Pre-clinical efficacy results published in Nature Communications SHIP 23.72% – News: Enters agreement to acquire a modern Capesize vessel ONTX 13.29% – News: Presents data at the 2017 AACR Annual Meeting ACLZ 9.00% – News: Names new VP of sales EARK 4.21% – News: Magnolia Solar subsidiary awarded a new U.S. patent TGEN 2.71% – News: Presenting as SAE World Congress on April 4 EMMD 1.85% – News: Acquires TravelsHunter.com…

Continue Reading

TuesdayApr 04, 2017 3:50 pm

NetworkNewsBreaks – InMed Pharmaceuticals, Inc. (IMLFF) Takes Aim at Rare Skin Diseases with INM-750

Epidermolysis bullosa (EBS) is a group of rare inherited skin diseases that unfortunately have no currently approved or known cure or treatment. InMed Pharmaceuticals, Inc. (OTCQB: IMLFF) has developed INM-750 as the first therapy to specifically treat EBS. “Earlier this month, InMed filed an international Patent Cooperation Treaty application for intellectual and commercial protection of INM-750 and a cannabinoid-based therapy for EBS. This marks a significant milestone for the company, serving as validation for its efforts to develop new therapies based on cannabinoids and its unique approach to drug development. The company is using a proprietary bioinformatics assessment tool to…

Continue Reading

TuesdayApr 04, 2017 3:49 pm

NetworkNewsBreaks – CytoDyn Inc. (CYDY) Advances PRO 140 to Provide a Better Quality of Life for HIV Patients

More than 34 million people have died from HIV since it was first discovered in 1981, according to Healthline (http://nnw.fm/i9ptS). Although there is no known cure for the disease, CytoDyn Inc. (OTCQB: CYDY) is advancing its drug candidate toward providing a better life for HIV patients. “PRO 140 is currently one of the most advanced experimental monoclonal antibodies for HIV treatment, and CYDY believes that it will be beneficial to patients with complicating issues, such as those with single or multi-drug resistant viruses or those who have difficulty sticking to a daily drug regimen, as well as those who can’t…

Continue Reading

TuesdayApr 04, 2017 3:48 pm

NetworkNewsBreaks – ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV) Results from New Studies Match Previous Findings, CRV431 Targets Hepatitis B Surface Antigen (HBsAg)

ContraVir Pharmaceuticals (NASDAQ: CTRV) this morning released results from new studies that provide insight into the mechanism of action (MOA) of its hepatitis B virus CRV431. The new studies show that CRV431 potently blocks the interaction between hepatitis B surface antigen (HBsAg), a key HBV protein, and cyclophilin A, an important cellular protein. The new information could explain previous findings that the drug reduces HBsAg. High levels of HBsAg in HBV-infected patients is a predictor for progression of disease, including liver fibrosis, cirrhosis, and cancer. “Our finding that CRV431 targets hepatitis B surface antigen is promising because reducing or eradicating…

Continue Reading

TuesdayApr 04, 2017 11:19 am

NetworkNewsBreaks – Evoke Pharma (NASDAQ: EVOK) Moves Forward with Comparative Exposure PK Trial for Gimoti NDA Following Type A Meeting with FDA

Evoke Pharma (NASDAQ: EVOK) shares rallied as much as 11% this morning after the company provided details of its positive Type A meeting with the U.S. Food and Drug Administration (FDA). Evoke met with the FDA to finalize the design of the pivotal comparative exposure pharmacokinetic (PK) trial and to reach agreement on additional aspects of the Chemistry, Manufacturing & Controls (CMC) section of the New Drug Application (NDA) for Gimoti™ for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adult women. The pivotal comparative exposure PK trial will be conducted in healthy volunteers to demonstrate…

Continue Reading

Contact us: 212.418.1217